Power Law company profile

GenMark Diagnostics

Biotech & Life Sciences · Carlsbad, United States · Founded 2010 · IPO 2010 Unicorn

Leading provider of automated, multiplex molecular diagnostic testing systems

Valuation

$1.80B

Market cap · 2026

Revenue

$213M

Latest reported FY

EBITDA

$27M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Global footprint

Where GenMark Diagnostics has talent and traffic

AI talent share

0.7% of workforce is AI talent
(3 of 434 staff)

Core AI00%

Other AI30.69%

Non-AI workforce43199.31%

Workforce by country

5 countries with
team presence

🇺🇸 United States98.5%

🇲🇽 Mexico0.4%

🇪🇬 Egypt0.4%

🇩🇪 Germany0.4%

🇫🇷 France0.4%

5 countries shown

Patent intelligence

$38M patent portfolio · 23 active families

Estimated portfolio value

$38M

2.1% of market cap · 72.4× smaller than top peer Illumina ($2.7B)

23 active patent families

Where GenMark Diagnostics innovates AnalyteBiologyNucleic acidElectrochemical detectionFluidics

Where GenMark Diagnostics concentrates vs peers

Each axis is a top-10 topic across GenMark Diagnostics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about GenMark Diagnostics

An AI-synthesized read of the highest-engagement posts about GenMark Diagnostics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GenMark Diagnostics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles